Table 2.
SLMAP gene polymorphisms | Non diabetic controls (NDC) (N = 104) | T2DM patients without DR (DNR) (N = 160) | OR* (95% CI) P | T2DM patients with DR (N = 78) | OR* (95% CI)P |
---|---|---|---|---|---|
Controls vs T2DM | DNR vs DR | ||||
SLMAP (rs17058639)C > T | N (%) | N (%) | N (%) | ||
TT | 11 (10.6%) | 29 (18.1%) | Reference | 6 (7.7%) | Reference |
CT | 49 (47.1%) | 71 (44.4%) | 0.60 (0.26-1.39) 0.231 | 30 (38.5%) | 2.08 (0.77-5.60) 0.146 |
CC | 44 (42.3%) | 60 (37.5%) | 0.52 (0.22-1.22) 0.136 | 42 (53.8%) | 3.23 (1.22-8.52) 0.018 |
TT + CT | 60 (57.7%) | 100 (62.5%) | Reference | 36 (46.2%) | Reference |
CC | 44 (42.3%) | 60 (37.5%) | 0.77 (0.45-1.34) 0.357 | 42 (53.8%) | 1.82 (1.04-3.18) 0.035 |
T | 71 (34.1%) | 129 (40.3%) | Reference | 42 (26.9%) | Reference |
C | 137 (65.9%) | 191 (59.7%) | 0.75 (0.51-1.12) 0.160 | 114 (73.1%) | 1.76 (1.15-2.68) 0.009 |
SLMAP (rs1043045)C > T | |||||
CC | 11 (10.6%) | 31 (19.4%) | Reference | 9 (11.5%) | Reference |
CT | 51 (49.0%) | 70 (43.8%) | 0.56 (0.24-1.28)0.167 | 31 (39.7%) | 1.57 (0.66-3.73) 0.306 |
TT | 42 (40.4%) | 59 (36.9%) | 0.51 (0.22-1.19) 0.120 | 38 (48.7%) | 2.09 (0.89-4.92) 0.090 |
C | 73 (35.1%) | 132 (41.3%) | Reference | 49 (31.4%) | Reference |
T | 135 (64.9%) | 188 (58.8%) | 0.76 (0.51-1.12) 0.162 | 107 (68.6%) | 1.46 (0.97-2.20)0.068 |
SLMAP (rs1057719)A > G | |||||
GG | 11 (10.6%) | 30 (18.8%) | Reference | 8 (10.3%) | Reference |
AG | 50 (48.1%) | 71 (44.4%) | 0.59 (0.22-1.20) 0.215 | 32 (41.0%) | 1.73 (0.71-4.23) 0.226 |
AA | 43 (41.3%) | 59 (36.9%) | 0.51 (0.22-1.20) 0.125 | 38 (48.7%) | 2.28 (0.94-5.53) 0.070 |
G | 72 (34.6%) | 131 (40.9%) | Reference | 48 (30.8%) | Reference |
A | 136 (65.4%) | 189 (59.1%) | 0.75 (0.50-1.11) 0.150 | 108 (69.2%) | 1.49 (0.99-2.24) 0.058 |
NDC = Non diabetic controls; T2DM = Type 2 Diabetes mellitus; DNR = Diabetic non-retinopathy; DR = Diabetic retinopathy; *Age and gender adjusted odds ratio and p-value; significant values shown in bold.